Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Familial Chylomicronemia Clear all

Terminated Phase 3 Interventional Results available

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

NCT01589237

View directory record Official record

Conditions: Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
Interventions: LCQ908; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Seatlle, Washington

Source: ClinicalTrials.gov public record

Updated Nov 14, 2016 · Synced May 22, 2026, 3:02 AM EDT

Active, not recruiting Phase 3 Interventional Results available

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

NCT05089084

View directory record Official record

Conditions: Familial Chylomicronemia
Interventions: Plozasiran, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Boca Raton, Florida • Suwanee, Georgia • Indianapolis, Indiana + 5 more

Source: ClinicalTrials.gov public record

Updated Feb 3, 2026 · Synced May 22, 2026, 3:02 AM EDT

Active, not recruiting Phase 3 Interventional

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

NCT05130450

View directory record Official record

Conditions: Familial Chylomicronemia Syndrome
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 7
States / cities: Huntington Beach, California • Boca Raton, Florida • Park Ridge, Illinois + 3 more

Source: ClinicalTrials.gov public record

Updated Dec 11, 2025 · Synced May 22, 2026, 3:02 AM EDT

Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

NCT01514461

View directory record Official record

Conditions: Familial Chylomicronemia Syndrome (FCS)
Interventions: LCQ908, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seatlle, Washington

Source: ClinicalTrials.gov public record

Updated Jun 2, 2015 · Synced May 22, 2026, 3:02 AM EDT

Active, not recruiting Phase 3 Interventional

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

NCT05185843

View directory record Official record

Conditions: Familial Chylomicronemia Syndrome
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Huntington Beach, California • Boca Raton, Florida • Ann Arbor, Michigan + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 11, 2025 · Synced May 22, 2026, 3:02 AM EDT

Withdrawn Phase 2 Interventional

Alipogene Tiparvovec for the Treatment of LPLD Patients

NCT02904772

View directory record Official record

Conditions: LPL Deficiency
Interventions: alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Aug 16, 2017 · Synced May 22, 2026, 3:02 AM EDT

Completed Phase 3 Interventional Results available

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

NCT02211209

View directory record Official record

Conditions: Familial Chylomicronemia Syndrome
Interventions: Volanesorsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 11
States / cities: Encinitas, California • San Francisco, California • Kansas City, Kansas + 8 more

Source: ClinicalTrials.gov public record

Updated Apr 12, 2022 · Synced May 22, 2026, 3:02 AM EDT

Completed Phase 3 Interventional Results available

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

NCT04568434

View directory record Official record

Conditions: Familial Chylomicronemia Syndrome
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 13 more

Source: ClinicalTrials.gov public record

Updated Mar 5, 2025 · Synced May 22, 2026, 3:02 AM EDT

Terminated Phase 2 Interventional Results available

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

NCT01675154

View directory record Official record

Conditions: Type 1 Hyperlipoproteinemia
Interventions: SLx-4090 placebo, Orlistat Placebo, Orlistat, Slx-4090; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 100 Years

Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Source: ClinicalTrials.gov public record

Updated Aug 18, 2021 · Synced May 22, 2026, 3:02 AM EDT

Completed Phase 3 Interventional Results available

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

NCT02658175

View directory record Official record

Conditions: Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
Interventions: Volanesorsen; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Aug 25, 2021 · Synced May 22, 2026, 3:02 AM EDT

Completed Phase 2 Interventional Results available

Orlistat for the Treatment of Type I Hyperlipoproteinemia

NCT02767531

View directory record Official record

Conditions: Hyperlipoproteinemia Type I, Hypertriglyceridemia
Interventions: Orlistat; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 8 Years to 18 Years

Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Source: ClinicalTrials.gov public record

Updated Feb 7, 2023 · Synced May 22, 2026, 3:02 AM EDT

Available No phase listed Expanded access

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

NCT06796426

View directory record Official record

Conditions: Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
Interventions: Plozasiran; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 15 Years and older

U.S. locations: 1
States / cities: Pasadena, California

Source: ClinicalTrials.gov public record

Updated Mar 2, 2026 · Synced May 22, 2026, 3:02 AM EDT

Approved For Marketing No phase listed Expanded access

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

NCT06360237

View directory record Official record

Conditions: Familial Chylomicronemia Syndrome
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

U.S. locations: 1
States / cities: Carlsbad, California

Source: ClinicalTrials.gov public record

Updated Dec 26, 2024 · Synced May 22, 2026, 3:02 AM EDT

Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

NCT06471543

View directory record Official record

Conditions: Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Interventions: RN0361; Drug
Lead sponsor: Ikaria Bioscience Pty Ltd; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Tamarac, Florida • Versailles, Kentucky • Dilworth, Minnesota + 3 more

Source: ClinicalTrials.gov public record

Updated Dec 29, 2025 · Synced May 22, 2026, 3:02 AM EDT